DelveInsight’s Trending Reports 2022: Ehlers-Danlos Syndrome Market, X Linked Hypophosphatemia Market, Thyroid Eye Disease Market, Primoridal Dwarfism Market, Sialidosis Market.
Ehlers-Danlos Syndrome Market Ehlers-Danlos syndrome (EDS) is a disease that weakens the connective tissues of your body. These are things like tendons and ligaments that hold parts of your body together. EDS can make your joints loose and your skin thin and easily bruised. It also can weaken blood vessels and organs. Some facts of Ehlers-Danlos Syndrome Market Report are: · The combined prevalence of all types of Ehlers-Danlos syndrome appears to be at least 1 in 5,000 individuals worldwide. · Vascular EDS is reported to have a prevalence of 1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1 in a million people. · The estimated prevalence for all EDS varies between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10% of cases. View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market Some of Ehlers-Danlos Syndrome Companies are: · Aventis Pharmaceuticals · EVAMED · Acer Pharma · And Many Others View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market Ehlers-Danlos Syndrome Therapies are: · Celiprolol · Irbesartan · And Many Others X Linked Hypophosphatemia Market X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets. Some facts of X Linked Hypophosphatemia Market Report are: · According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000. · As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States · According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease. · The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000. View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market Some of X Linked Hypophosphatemia Companies are: · Ultragenyx · Validus Pharmaceuticals · Prospec-Tany Technogene Ltd · Merck KGaA · Zeria Pharmaceutical Co., Ltd · Smith & Nephew · Narang Medical Limited · Eli Lilly and Company · F. Hoffmann-La Roche Ltd · And Many Others View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market X Linked Hypophosphatemia Therapies are: · Burosumab · Crysvita · And Many Others Thyroid Eye Disease Market Thyroid eye disease (TED)—also known as Graves’ Orbitopathy or Ophthalmopathy—is an autoimmune condition. It occurs when the body’s immune system attacks the tissue surrounding the eye causing inflammation in the tissues around and behind the eye. It appears that the same antibody that can cause thyroid dysfunction may also have an "attraction"to tissuessurrounding the eyes causing the onset of Graves' Ophthalmopathy. Moreover, the disease is categorized as mild, moderate, and severe. Some of Thyroid eye disease Facts · In a study by Zagaria et al. , it was observed that approximately 25‐30% of patients with Graves’ disease have clinical evidence of Graves’ ophthalmopathy. · As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men). · The study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO) occurs mainly, but not exclusively, in patients with Graves’ disease. However, only about <50% of Graves’ patients have clinically apparent ophthalmopathy, where the approximate prevalence is 0.25%. · According to a review article titled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant in approximately 50% of patients with Graves' disease, and severe forms affects less than 5% of patients. View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market Some of Thyroid eye disease Companies · Immunovant Sciences · Horizon Therapeutics · And Many Others Thyroid eye disease Drugs Covered: · IMVT‐1401 · Teprotumumab · And Many Others View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market Primoridal Dwarfism Market Primordial dwarfism is a rare and often dangerous group of genetic conditions that result in a small body size and other growth abnormalities. Signs of the condition first appear in the fetal stage and continue through childhood, adolescence, and adulthood. Some facts of Primordial Dwarfism Market Report · Primordial Dwarfism Market size is expected to change for 7MM during the forecast period of 2018-30. · Its prevalence report estimates 4 million babies to die in the ﬁrst 4 weeks of life (the neonatal period) with almost 99 % of neonatal deaths (Lawn et al. 2011; Cous-ens et al. 1995). · The modern prevalence of MOPDII is unknown, but between 150 and 200 cases are reported worldwide each year (Bober and Jackson, 2017). · All types of primordial dwarfism are caused by changes in genes. Different gene mutations cause the different conditions that make up primordial dwarfism. · Primordial dwarfism can be difficult to diagnose. This is because the small size and low body weight could be a sign of other things, such as poor nutrition or a metabolic disorder. To get more detailed insight on Primordial Dwarfism Market Report @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market Some of Primordial Dwarfism Companies are: · GeneScience Pharmaceuticals · Merck · Genentech, Inc. · Pfizer · Novo Nordisk · EMD Serono · And Many Others Primordial Dwarfism Therapies are: · Jintrolong® low dose group · Recombinant human growth hormone (r-hGH) · Somatropin · And Many Others To get more detailed insight about Primordial Dwarfism Therapies @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market Sialidosis Market Sialidosis is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this enzyme results in an abnormal accumulation of complex carbohydrates known as mucopolysaccharides, and of fatty substances known as mucolipids. Both of these substances accumulate in bodily tissues. There are four types of Sialidosis: Each type of Sialidosis is characterized by the age of onset and by the type of physical and mental manifestations of this disorder. Some of Sialidosis facts · As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry. · As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age. · According to NORD, Sialidosis affects males and females in equal number. · The prevalence is estimated to be less than 1/1,000,000. View Report: https://www.delveinsight.com/report-store/sialidosis-market Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach. Some of Newly Launched Report: Acute Lung Injury Market Adamantinoma Market Defibrillators Market Urolithiasis Market Cardiac Resynchronization Therapy Device Market Aesthetic Implants Market Alzheimer Disease Market Central Venous Catheters Market Biochips Market Alopecia Market Cardiac Monitoring Devices Market Biliary Tumor Market Foot And Ankle Devices Market Hyperuricemia Market Invasive Candidiasis Market Global Electrophysiology Devices Market Neurovascular Devices Market Blood Glucose Monitoring Systems Market Neurostimulation Devices Market Human Papilomavirus Market Capnography Device Market Ventilator Market Breast Pumps Market Metastatic Bone Pain Market Brain Aneurysm Stents Market Atypical Hemolytic Uremic Syndrome Ahus Market 2 Deletion Syndrome Market X Linked Hypophosphatemia Market Parkinsons Disease Related Dementia Market Ocular Motility Disturbance Market Palmar Hyperhidrosis Market Size Pulse Oximeters Market Diagnostic Imaging Equipment Market Continuous Renal Replacement Therapy Machines Market Pain Management Devices Market Glycogen Storage Disease Market Rituximab Biosimilars Insight Epithelial Ovarian Cancer Market Cardiac Biomarkers Testing Devices Market Chronic Myelogenous Leukemia Market Bone Grafts And Substitutes Market Idiopathic Membranous Nephropathy Market Advanced Renal Cell Carcinoma Market Sialidosis Market Prosthetic Joint Infection Market Microsatellite Stable Colorectal Cancer Market Higher-Risk Chronic Myelomonocytic Leukemia Market Chondrosarcoma Market Car T Therapy For Acute Lymphoblastic Leukemia All Market Related Blogs: Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment Mapping the Biggest Pharmaceutical Companies by Continents Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers Major Drugs Decisions for Cardiovascular Diseases to Watch Through 2022 Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021 Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market Cybersecurity in Healthcare: Major Threats and Challenges Top Drugs To Watch in HIV (2025) About Delveinsight: DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems. Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: firstname.lastname@example.org Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com Connect With Us at: LinkedIn | Facebook | Twitter